What happenedModerna and Merck said Wednesday their experimental mRNA cancer vaccine successfully reduced recurrence of melanoma, and prevented the deadly skin cancer from spreading to other organs, in a large trial. The results “mark the first successful late-stage trial for a personalized mRNA cancer therapy,” The Wall Street Journal said, “validating decades of research” and “paving the way for a potentially new life-extending treatment” for people diagnosed with melanoma and other cancers.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Join 350,000+ subscribers and keep yourself informed with a selection of
